Summarized by Masters of Longevity from Longevity Technology.
News about a biotech starting dosing in an early-stage Parkinson’s clinical trial, previewing a short clinical-update article focused on trial design and objectives.
Key Takeaways
- The RESET study is a randomized double‑blind placebo‑controlled Phase 2a trial enrolling about 30 Parkinson's patients across two dose levels and placebo.
- Primary endpoints are safety, tolerability and pharmacokinetics with secondary assessments of energy metabolism, inflammation biomarkers and clinical outcomes.
- A completed Phase 1 reported increased systemic exposure and measurable cerebrospinal fluid concentrations of the micellar trans‑resveratrol formulation with no serious adverse events.
